Amid revenue dip, Pfizer CEO Albert Bourla is focused on 'what's next'
Pfizer suffered its first quarterly revenue dip since its BioNTech-partnered Covid vaccine was authorized in 2020, CEO Albert Bourla revealed on Tuesday. And if that isn’t bad enough, he expects patent expiries to cost the company around $17 billion between 2025 and 2030.
Which is why, he emphasized on the Q3 call, “It’s all about what’s next.”
Bourla outlined ambitious plans to bring 19 new products or indications to market over the next year and a half.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.